<DOC>
	<DOCNO>NCT00190021</DOCNO>
	<brief_summary>Conventional psychotropic medication may use treat behavioral disturbance psychotic symptom patient dementia drug choice treat delusion hallucination . However sensitivity side effect patient often restrict use agent ( 2 , 3 ) . Although , atypical antipsychotic advantage compare conventional neuroleptic , also associate side effect ( 5 , 6 ) . Cholinesterase inhibitor ( ChEIs ) enhance neuronal transmission increase availability acetylcholine muscarinic nicotinic receptor . According finding researcher ChEIs psychotropic effect may play important role control neuropsychiatric behavioral disturbance patient Alzheimer 's disease ( 7-10 ) . These agent may also contribute management disorder cholinergic system abnormality neuropsychiatric symptom visual hallucination ( 11 ) . Donepezil piperidine-based reversible , noncompetitive ChEI , indicate management patient Alzheimer 's disease mild moderate severity ( 12-14 ) . Preliminary observation suggest possible value ChEIs amelioration psychotic symptom patient dementia Alzheimer 's type ( DAT ) , dementia Lewy body patient suffer Parkinson 's disease ( 11-18 ) . The result study ( 18 ) indicate addition donepezil perphenazine result qualitatively superior clinical gain compare high dos neuroleptic therapy without donepezil . The finding pilot study although impressive , stem data regard rather small sample . The present ( second ) phase study include large sample patient . We intend examine 80 inpatient , age 65-90 year old , suffer DAT .</brief_summary>
	<brief_title>Donepezil Treatment Psychotic Symptoms Dementia Patients</brief_title>
	<detailed_description>Criteria inclusion study : 1 ) DSM-IV diagnosis Dementia Alzheimer type psychotic symptom hallucination delusion , aggression/agitation , irritability , disinhibition call administration antipsychotic drug ; 2 ) duration psychotic symptom least 2 week begin treatment ; 3 ) lack improvement psychotic symptom ( less 25 % Positive Negative Symptoms Scale ( PANSS ) perphenazine treatment ( 8 mg/day ) least three week ; 4 ) drug regimen physical disease patient unchanged least three month study . Exclusion criterion include : 1 ) vascular dementia ; 2 ) concurrent Axis I DSM-IV diagnosis ( delirium , schizophrenia , delusional disorder , affective disorder ) 3 ) significant medical illness ( cardiovascular , liver , renal , endocrinal , vitamin B12 folic acid deficiency , neurological illness ) ; 4 ) drug or/and alcohol addiction . The study design double blind group study , last 9 week . Complete physical laboratory examination perform inpatient . Subjects randomize 1:1 fashion receive treatment 4 mg perphenazine 5 mg donepezil placebo addition perphenazine treatment ( 8 mg/day ) receive past 3 week ( baseline ) . According mental state ( improvement le 20 % PANSS score ) , perphenazine dose elevate 4 mg/day maximum 16 mg/day first group , donepezil dose increase 5 mg/day maximum 10 mg/day second group ) placebo elevate 2 capsules/day third group . All preparation administer identical capsule make professional pharmacist , supply individual number-coded package . Assessments psychotic symptom do use PANSS CGI baseline repeat weekly . Assessments extrapyramidal side effect do use AIMS baseline repeat every week . In addition , begin end study , patient assess MMSE GDS . Complete blood profile , urine analysis perform screen week 9 . References 1 . Evans DA . Estimated prevalence Alzheimer 's disease United States . Milbank Q 1990 ; 68:267-89 . 2 . Schneider LS . Pharmacologic management psychosis dementia . J Clin Psychiatry 1999 ; 60 ( Suppl 8 ) :54-60 . 3 . Tariot PN . Treatment agitation dementia . J Clin Psychiatry 1999 ; 60 ( Suppl 8 ) :11-20 . 4 . Levy ML , Cummings JL , Kahn-Rose R. Neuropsychiatric symptom cholinergic therapy Alzheimer 's disease . Gerontology 1999 ; 45 ( Suppl 1 ) :15-22 . 5 . Casey DE . Side effect profile new antipsychotic agent . J Clin Psychiatry 1996 ; 57 ( Suppl 11 ) :40-5 . 6 . Zayas EM , Grossberg GT . The treatment psychosis late life . J Clin Psychiatry 1998 ; 59 ( Suppl 1 ) :5-10 . 7 . Rogers SL , Doody RS , Mohs RC , et al . Donepezil improve cognition global function Alzheimer disease : 15-week , double-blind , placebo-controlled study . Donepezil Study Group . Arch Intern Med 1998 ; 158 ( 9 ) :1021-31 . 8 . Wengel SP , Roccaforte WH , Burke WJ . Donepezil improve symptom delirium dementia : implication future research . J Geriatr Psychiatry Neurol 1998 ; 11 ( 3 ) :159-61 . 9 . Mega MS , Masterman DM , O'Connor SM , et al . The spectrum behavioral response cholinesterase inhibitor therapy Alzheimer disease . Arch Neurol 1999 ; 56:1388-93 . 10 . Burt T. Donepezil related cholinesterase inhibitor mood behavioral control agent . Curr Psychiatry Rep 2000 ; 2:473-8 . 11 . Burke WJ , Roccaforte WH , Wengel SP . Treating visual hallucination donepezil . Am J Psychiatry 1999 ; 156:1117-8 . 12 . Rogers SL , Friedhoff LT . The efficacy safety donepezil patient Alzheimer 's disease : result US Multicentre , Randomized , Double-Blind , Placebo- Controlled Trial . The Donepezil Study Group . Dementia 1996 ; 7 ( 6 ) :293-303 . 13 . Burns A , Rossor M , Hecker J , et al . The effect donepezil Alzheimer 's disease - result multinational trial . Dement Geriatr Cogn Disord 1999 ; 10:237-44 . 14 . Dooley M , Lamb HM . Donepezil : review use Alzheimer 's disease . Drugs Aging 2000 ; 16:199-226 . 15 . Cummings JL , Gorman DG , Shapira J. Physostigmine ameliorate delusion Alzheimer 's disease . Biol Psychiatry 1993 ; 33:536-41 . 16 . Kaufer DI , Cummings JL , Christine D. Effect tacrine behavioral symptom Alzheimer 's disease : open-label study . J Geriatr Psychiatry Neurol 1996 ; 9:1-6 . 17 . McKeith I , Del Ser T , Spano P , et al . Efficacy rivastigmine dementia Lewy body : randomise , double-blind , placebo-controlled international study . Lancet 2000 ; 356 ( 9247 ) :2031-6 . 18 . Bergman J , Lerner V. Successful use donepezil treatment psychotic symptom patient Parkinson 's disease . Clin Neuropharmacol 2002 ; 25:107-10 . 19 . Folstein MF , Folstein SE , McHugh PR . `` Mini-mental state '' . A practical method grade cognitive state patient clinician . J Psychiatr Res 1975 ; 12:189-98 . 20 . Reisberg B , Ferris SH , de Leon MJ , et al . Global Deterioration Scale ( GDS ) . Psychopharmacol Bull 1988 ; 24:661-3 . 21 . Pollock BG , Mulsant BH , Rosen J , et al . Comparison citalopram , perphenazine , placebo acute treatment psychosis behavioral disturbance hospitalize , demented patient . Am J Psychiatry 2002 ; 159:460-5 . 22 . Sweet RA , Pollock BG , Mulsant BH , et al . Pharmacologic profile perphenazine 's metabolite . J Clin Psychopharmacol 2000 ; 20:181-7 . 23 . Kay S , Opler L , Fiszbein A . Positive Negative Syndrome Scale ( PANSS ) Manual . North Tonawanda , NY : Multi-Health Systems ; 1986 . 24 . Guy W. ECDEU Assessment Manual Psychopharmacology , revise . Washington , DC : US Department Health , Education Welfare ; 1976 .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>age : 6590 DSMIV diagnosis Alzheimer 's type dementia inclusion psychotic symptom : hallucination delusion , aggression/agitation , irritability disinhibition call adminstration antipsychotic drug duration psychotic symptom least 2 week start treatment lack improvement psychotic symptom perphenazine treatment least 3 week vascular demential concurrent Axis I DSMIV diagnosis ( delirium , schizophrenia , delusional disorder affective disorder ) significant medical illness ( cardiovascular , liver , renal , edocrinal , B12 folic acid deficience neurological illness ) drug alcohol addiction</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>Alzheimer 's type dementia</keyword>
	<keyword>donepezil</keyword>
	<keyword>double-blind</keyword>
</DOC>